a year ago
EnteroBiotix Raises £27M to Advance Gut Microbiome Therapies
EnteroBiotix, a clinical-stage biotechnology company, has raised £27 million in funding to advance its lead product candidate and progress its pipeline for treating conditions linked to a disrupted gut microbiome.
ProblemHealthcare
"Patients suffering from serious conditions linked to the gut microbiome, such as Irritable Bowel Syndrome, liver cirrhosis, and hepatic encephalopathy, need effective treatments to restore the microbiome and alleviate their symptoms."
Solution
"EnteroBiotix is developing a pipeline of full-spectrum microbial therapeutics, tailored to specific patient needs, to fortify and restore the microbiome, providing innovative treatments for patients with serious unmet medical needs."
